A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2022-04-25
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to compare the amount of selpercatinib that gets into the
blood stream and how long it takes the body to get rid of it, when given as three different
formulations in adult healthy participants. The information about any adverse effects
experienced will be collected and the tolerability of selpercatinib will also be evaluated.
The study may last up to 59 days including the 28 days of screening period.